ARTICLE | Company News
Opsona, Wyeth deal
February 20, 2006 8:00 AM UTC
Opsona and WYE partnered to discover, develop and commercialize compounds targeting Opsona's toll-like receptor 14 (TLR14) for autoimmune and inflammatory diseases. Opsona will receive an upfront paym...